A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 22 Feb 2018 Planned End Date changed from 15 Jun 2021 to 15 Oct 2020.
- 22 Feb 2018 Planned primary completion date changed from 15 Apr 2021 to 14 Aug 2020.
- 22 Nov 2017 New trial record